Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern
- 18 December 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Parasitenkunde
- Vol. 112 (3), 1001-1009
- https://doi.org/10.1007/s00436-012-3222-1
Abstract
Visceral leishmaniasis (VL) remains a major health problem in old world, and India accounts for half of the world burden. The widespread emergence of resistance to standard drug in India poses a major obstacle in the control of leishmaniasis. Post-Kala-Azar dermal leishmaniasis (PKDL) is considered as main source of drug resistance. Experimental data indicate that resistance against newer drugs is also imminent. Therefore, in vitro studies were carried out to test minimum parasiticidal concentration of five conventional and newly introduced anti-leishmanial drugs against 20 field isolates of Leishmania donovani obtained from visceral and post-Kala-Azar dermal leishmaniasis patients of India. Study revealed wide range of variation in minimum inhibitory concentration of sodium antimony gluconate (SAG). PKDL isolates displayed significantly lower susceptibility to SAG and miltefosine than VL isolates with P value of 0.0006 and 0.0243, respectively. All clinical isolates had higher IC50 value for paromomycin and miltefosine as compared to reference strain indicating their vulnerability to develop unresponsiveness. However, isolates were uniformly susceptible to pentamidine and amphotericin B. The results of gene expression analysis of AQP1 were largely in agreement with phenotypic drug sensitivity results. Interestingly, significant down-regulation of AQP1 was observed in PKDL isolates as compared to VL isolates indicating their increased propensity for drug unresponsiveness. However, no significant difference in mRNA expression of LdMT and LdRos3 gene was found for two groups. The present study unravels valuable baseline scientific data showing variation in the drug susceptibility pattern in the L. donovani isolates. The information might have impact on the management and control of Indian visceral leishmaniasis.Keywords
This publication has 26 references indexed in Scilit:
- In Vitro Susceptibility of Field Isolates of Leishmania donovani to Miltefosine and Amphotericin B: Correlation with Sodium Antimony Gluconate Susceptibility and Implications for Treatment in Areas of EndemicityAntimicrobial Agents and Chemotherapy, 2009
- Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management2007
- Genetic diversity of Leishmania amazonensisstrains isolated in northeastern Brazil as revealed by DNA sequencing, PCR-based analyses and molecular karyotypingKinetoplastid Biology and Disease, 2007
- Diffuse cutaneous leishmaniasis responds to miltefosine but then relapsesBritish Journal of Dermatology, 2007
- Chemotherapy of Leishmaniasis: Past, Present and FutureCurrent Medicinal Chemistry, 2007
- Gene Expression Analysis of the Mechanism of Natural Sb(V) Resistance in Leishmania donovani Isolates from NepalAntimicrobial Agents and Chemotherapy, 2005
- Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasisParasitology International, 2005
- Drug Uptake and Modulation of Drug Resistance in Leishmania by an AquaglyceroporinPublished by Elsevier BV ,2004
- Leishmania donovani: Intraspecific Polymorphisms of Sudanese Isolates Revealed by PCR-based Analyses and DNA SequencingExperimental Parasitology, 2001
- Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas?1992